Loading organizations...
Key people at Ochre.
Ochre was founded by Sasha Basso (Founder).
Ochre Bio develops RNA-based therapies specifically targeting chronic liver diseases by harnessing a comprehensive human discovery platform. The company integrates proprietary gene perturbation atlases with patient disease atlases, leveraging artificial intelligence to predict novel drug targets. This approach is validated through advanced human models, including perfused livers and diseased tissue slices, enabling the rapid and accurate modeling of complex biological processes to accelerate the discovery and development of new treatments.
Founded in September 2019 by Jack O'Meara and Quin Wills in Oxford, England, Ochre Bio emerged from the founders' shared insight into the transformative potential of human-centric data and sophisticated biological modeling for liver therapeutics. O'Meara, serving as CEO, and Wills, as CSO, bring together extensive expertise in genomics, AI, and drug development, forming a robust foundation for the company's innovative scientific strategy.
The company engages with major pharmaceutical partners, such as GSK and Boehringer Ingelheim, to advance its pipeline and bring promising therapies to market. Ochre Bio's ultimate vision is to eradicate the necessity for liver transplants, thereby addressing a significant global health challenge. They are dedicated to fundamentally altering the treatment paradigm for liver diseases by offering curative solutions that move beyond current transplantation limitations.
Ochre Ventures is a specialized venture capital firm focused on investing in and scaling First Nations businesses across Australia[1]. Its mission centers on supporting Indigenous-led enterprises, with an investment philosophy emphasizing growth and impact within Aboriginal and Torres Strait Islander communities. The firm targets key sectors relevant to First Nations economies, such as business development and entrepreneurship, contributing to the startup ecosystem by providing targeted capital and expertise to underrepresented founders.
Ochre Bio, a distinct biotech portfolio company, develops RNA-based therapies to prevent chronic liver disease, addressing a leading cause of premature death in industrialized nations[3][4][6]. It serves patients with conditions like NASH, alcohol-mediated liver issues, and transplant needs, using a platform combining machine learning, genomic phenotyping, cellular imaging, and experimental biology on human organs. Recent growth includes a $34M Series A round backed by investors like Khosla Ventures and notable individuals, with advanced programs already perfusing leads in human livers[3].
Ochre Ventures emerged as a dedicated fund without specified founding details in available data, but its focus has evolved to specialize in First Nations business growth in Australia, filling a niche for Indigenous venture capital[1].
Ochre Bio was founded in 2019 in Oxford, UK, by a team leveraging expertise in genomics and AI to tackle liver disease[6]. The idea stemmed from gaps in traditional drug discovery, prompting a novel approach integrating digital data and human organ testing for faster RNA therapy validation. Early traction included rapid progression to human liver perfusion for lead candidates and securing Series A funding from prominent VCs and biotech leaders like Alice Zhang of Verge Genomics[3].
Ochre Ventures rides the global trend of impact investing and Indigenous economic reconciliation, particularly in Australia where First Nations startups face capital access barriers. Timing aligns with rising demand for diverse-led innovation amid reconciliation efforts, bolstered by government and corporate DEI initiatives. It influences the ecosystem by catalyzing Indigenous entrepreneurship, potentially reshaping sectors like resources and services[1].
Ochre Bio capitalizes on the AI-biotech convergence and RNA therapeutics boom, post-mRNA vaccine success, targeting the massive unmet need in liver disease (third leading premature death cause). Market forces like aging populations and rising metabolic disorders (e.g., NASH) favor its platform, which accelerates discovery amid high failure rates in traditional pharma. As a pioneer in human-organ-validated RNAis, it pushes the ecosystem toward faster, data-driven therapies, influencing competitors in genomics and precision medicine[3][4][6].
For Ochre Ventures, expansion into larger funds or pan-Pacific Indigenous deals seems likely, shaped by Australia's reconciliation momentum and global impact VC growth; its influence could grow by mentoring the next wave of First Nations unicorns.
Ochre Bio's trajectory points to clinical milestones in transplant and NASH programs, with AI-RNA synergies and trends like multi-omics driving further funding and partnerships. Evolving regulations for rapid orphan indications may amplify its role, positioning it as a liver disease leader while inspiring platform-based biotech.
These entities exemplify niche innovation—Ochre Ventures empowering cultural economies, Ochre Bio revolutionizing disease prevention—both primed for outsized impact in their domains[1][3].
Key people at Ochre.
Ochre was founded by Sasha Basso (Founder).
